Patents by Inventor Lorraine Thompson

Lorraine Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240033359
    Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules provided herein.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 1, 2024
    Inventors: Gary SHAPIRO, Xingyue HE, Mei Rosa NG, Lorraine THOMPSON, Elena DE JUAN FRANCO, Steven VANCE
  • Publication number: 20230406954
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Application
    Filed: June 28, 2023
    Publication date: December 21, 2023
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Patent number: 11746158
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: September 5, 2023
    Assignee: Crescendo Biologics Limited
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Publication number: 20220112305
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Application
    Filed: October 22, 2021
    Publication date: April 14, 2022
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Patent number: 11236174
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 1, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Patent number: 10975161
    Abstract: The disclosure relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: April 13, 2021
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossant, Thomas Sandal, Lorraine Thompson
  • Publication number: 20200392244
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Application
    Filed: January 12, 2017
    Publication date: December 17, 2020
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossant, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Publication number: 20190023807
    Abstract: The disclosure relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossat, Thomas Sandal, Lorraine Thompson